Chinese Distribution Contract Extended for an Additional 4 Years
February 05 2010 - 11:19AM
PR Newswire (US)
FOUNTAIN HILLS, Ariz., Feb. 5 /PRNewswire-FirstCall/ -- Sunridge
International (OTC:SNDZ) (BULLETIN BOARD: SNDZ) announced today
that they have extended the exclusive distribution agreement with
Beijing Vision World Trading Co., Ltd. for an additional 4 years.
"I am very happy to sign this agreement," states G. Richard Smith,
CEO of Sunridge International (http://www.sunridgeint.com/). "We
have worked closely with Beijing Vision World Trading Co., Ltd.
(BV) over the last 3 1/2 years to complete the registration process
for Pneumatic Trabeculoplasty, 'PNT' in China." PNT is a
two-minute, noninvasive, cost effective, alternative treatment for
glaucoma and ocular hypertension, which was developed and patented
by Ophthalmic International (http://www.oi-pnt.com/), Sunridge
Internationals wholly owned subsidiary. "The registration process
for a medical device and treatment is very strict in China. It is a
very long, expensive and tedious procedure," states Mr. Smith. BV
has worked tirelessly over the last 3 1/2 years at a tremendous
financial cost to its company to compete this process. They have
performed several successful clinical trials at both private and
state military hospitals as part of this effort. With approval
expected in the very near future, BV is now concentrating on its
marketing efforts. They have ordered and received delivery on 5
units with a substantial number of disposable rings, to be placed
in 5 major hospitals in Beijing. These hospitals will be used as
models for the rest of the country. They are currently negotiating
with a number of companies to act as sub distributors to expand
distribution throughout all of China. They are attending different
levels of Academy Conferences and Exhibitions as part of their
"PNT" awareness program. Doctors and distributor personal are being
trained. BV is doing everything possible to ensure the successful
marketing of PNT in China. Mr. Smith goes on to say, "that this is
a significant event for OI. China is a major market for us, with
millions of Glaucoma patients. The fact that a 'PNT' treatment
lasts 3-4 months as a rule, with little or no side effects, makes
it a very viable treatment for not only for the people of China,
but for people everywhere. We expect that this will prove to be a
very profitable market for OI." Forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Investors are
cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance
of the company's products, increased levels of competition for the
company, new products and technological changes, the company's
dependence on third-party suppliers, and other risks detailed from
time to time in the company's periodic reports filed with the
Securities and Exchange Commission. CONTACT: Jeff Smith of Sunridge
International, +1-480-837-6165, DATASOURCE: Sunridge International
CONTACT: Jeff Smith of Sunridge International, +1-480-837-6165, Web
Site: http://www.sunridgeint.com/
Copyright